EFFECTS OF EMPAGLIFLOZIN ON SALT-SENSITIVE HYPERTENSION AND RENAL INFLAMMATION IN RAT
- Authors
- Kim, G. H.; Jo, C. H.; Kim, S.
- Issue Date
- Jun-2018
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF HYPERTENSION, v.36, pp.E76 - E76
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF HYPERTENSION
- Volume
- 36
- Start Page
- E76
- End Page
- E76
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3115
- DOI
- 10.1097/01.hjh.0000539179.77461.a3
- ISSN
- 0263-6352
- Abstract
- Objective:
Renal inflammation may have a role in salt-sensitive hypertension. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors were reported to exert blood pressure lowering in type 2 diabetes mellitus, whether they have a role in non-diabetic kidney diseases is not clear. This study was undertaken to investigate whether salt-sensitive hypertension and its accompanying renal inflammation are ameliorated by SGLT2 inhibition.
Design and method:
The animal model of salt-sensitive hypertension was established by salt loading in uninephrectomized rats. Male Sprague-Dawley rats were randomly divided into 3 groups: sham controls (SC, n = 4), uninephrectomized controls (UC, n = 4), and empagliflozin-treated rats (ET, n = 5). All rats were fed a rodent diet with 8% NaCl throughout the study period. Empagliflozin (20 mg/kg/d) was orally administered for 3 weeks after uninephrectomized rats were stabilized over 2 weeks. Systolic blood pressures (SBPs) were weekly measured, and kidneys were harvested for qPCR at the end of animal experiment.
Results:
At baseline, SBPs were 122 ± 4, 127 ± 1, and 125 ± 3 mmHg in SC, UC, and ET, respectively. At the end of animal experiment, SBP in UC was higher than that in SC (167 ± 4 vs. 137 ± 6 mmHg, P < 0.01). However, ET had a lower SBP (146 ± 3 mmHg) compared with UC (P < 0.05). As expected, urinary glucose excretion was remarkable in ET (2.61 ± 0.59 mmol/d/100 g BW versus 0 in controls). Whereas natriuresis was not different between groups, urinary excretion of osmoles in ET (29.8 ± 3.6 mmol/d/100 g BW, P < 0.01) was higher than that in SC (20.6 ± 2.3 mmol/d/100 g BW) or UC (19.3 ± 1.4 mmol/d/100 g BW). Compared with SC, the mRNA expression level of IL-1β (268 ± 91%, P < 0.05), RANTES (167 ± 20%, P < 0.05), and gp91phox (300 ± 36%, P < 0.05) were increased in UC but ameliorated in ET (IL-1β, 159 ± 29%; RANTES, 87 ± 34%; gp91phox, 142 ± 74%, all P < 0.05).
Conclusions:
Empagliflozin was effective in controlling salt-sensitive hypertension induced by renal mass reduction, via glycosuria-driven osmotic diuresis rather than natriuresis. The upregulation of renal inflammation in salt-sensitive hypertension may be relieved by empagliflozin treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3115)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.